Drug and Alcohol Rehabilitation: Treatment of Obese Diabetics.

Treatment of obese diabetics.

Filed under: Drug and Alcohol Rehabilitation

Adv Exp Med Biol. 2012; 771: 459-64
Svacina S

Fat accumulation is a typical phenomenon in the pathogenesis of Type 2 diabetes. Also Type 1 diabetics are getting obese these days living in an environment with typical caloric overfeeding and low physical activity. Weight reduction is an important part of therapy in all obese diabetic patients. Orlistat is the only accessible antiobesity drug today. Weight neutral antidiabetics like metformin and DPP-4 inhibitors can be also used. Incretin analogues (exenatide and liraglutide) are also very important drugs inducing weight loss in diabetic and also in nondiabetic patients. Insulin therapy causes mostly weight gain. Long acting insulin analogues are able to induce small weight loss in Type 1 diabetes or only a small weight increase or weight loss in Type 2 diabetic patients. Procedures of bariatric surgery are very important in the treatment being able to induce remission of Type 2 diabetes. Weight reduction can be supported also using the new class of antiadiabetic drugs- SGLT inhibitors which are blocking glucose absorption in kidneys. The use of new incretine analogues injected at the interval of one to two weeks is the most important strategy for the treatment of obese Type 2 diabetic patients and perhaps also of Type 1 diabetic patients even in combination with insulin.
HubMed – drug

Retinopathy in diabetes.

Filed under: Drug and Alcohol Rehabilitation

Adv Exp Med Biol. 2012; 771: 88-106
Tarr JM, Kaul K, Wolanska K, Kohner EM, Chibber R

With the incidence, and prevalence of diabetes mellitus increasing worldwide, diabetic retinopathy is expected to reach epidemic proportions. The aim of this chapter is to introduce diabetic retinopathy, a leading cause of blindness in people of the working age. The clinical course of retinopathy, anatomical changes, its pathogenesis and current treatment are described, followed by an overview of the emerging drug therapies for the potential treatment of this sight-threatening complication of diabetes.
HubMed – drug

Europe bets on drug discovery.

Filed under: Drug and Alcohol Rehabilitation

Nature. 2013 Feb 7; 494(7435): 20
Baker M

HubMed – drug

Assessing Similarity to Existing Drugs to Decide Whether to Continue Drug Development.

Filed under: Drug and Alcohol Rehabilitation

Stat Biopharm Res. 2012 Jan 1; 4(3): 293-300
Ma GJ, Chi E, Ibrahim JG, Parker RA

Developing a drug requires large investments, over many years, with dramatic increases in development costs at later stages. Thus, one wants to make a No Go decision on a compound early, unless evidence continues to suggest that the project will ultimately be successful, so that resources can be focused on the most promising compounds to benefit patients. Instead of predicting the probability of success of a Phase III study, our approach to this decision uses the Phase II study results to assess similarity of the novel compound to existing drugs that are classified by different decision categories, such as a clear Go decision (e.g., a clearly effective drug), a (unfortunately common) Not Sure decision (e.g., a potentially useful but not outstanding drug), and a clear No Go decision (e.g., a clearly not effective drug). We describe how this modeling can be done using both individual and binary endpoints and how results can be combined for several different endpoints. Potential extensions of the method are also discussed.
HubMed – drug

More Drug And Alcohol Rehabilitation Information…